LAB vs. CTKB, QTRX, EYPT, ADPT, PACB, NAUT, HBIO, IVAC, LUNA, and SOTK
Should you be buying Standard BioTools stock or one of its competitors? The main competitors of Standard BioTools include Cytek Biosciences (CTKB), Quanterix (QTRX), EyePoint Pharmaceuticals (EYPT), Adaptive Biotechnologies (ADPT), Pacific Biosciences of California (PACB), Nautilus Biotechnology (NAUT), Harvard Bioscience (HBIO), Intevac (IVAC), Luna Innovations (LUNA), and Sono-Tek (SOTK).
Cytek Biosciences (NASDAQ:CTKB) and Standard BioTools (NASDAQ:LAB) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, community ranking, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.
Cytek Biosciences received 14 more outperform votes than Standard BioTools when rated by MarketBeat users. However, 100.00% of users gave Standard BioTools an outperform vote while only 41.46% of users gave Cytek Biosciences an outperform vote.
69.5% of Cytek Biosciences shares are held by institutional investors. Comparatively, 53.7% of Standard BioTools shares are held by institutional investors. 15.9% of Cytek Biosciences shares are held by company insiders. Comparatively, 53.1% of Standard BioTools shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Cytek Biosciences has a net margin of -6.29% compared to Cytek Biosciences' net margin of -70.21%. Cytek Biosciences' return on equity of 0.00% beat Standard BioTools' return on equity.
Cytek Biosciences presently has a consensus price target of $9.00, suggesting a potential upside of 56.25%. Standard BioTools has a consensus price target of $3.58, suggesting a potential upside of 46.86%. Given Standard BioTools' higher probable upside, equities analysts clearly believe Cytek Biosciences is more favorable than Standard BioTools.
Cytek Biosciences has higher revenue and earnings than Standard BioTools. Cytek Biosciences is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.
Cytek Biosciences has a beta of 1.37, indicating that its share price is 37% more volatile than the S&P 500. Comparatively, Standard BioTools has a beta of 1.64, indicating that its share price is 64% more volatile than the S&P 500.
In the previous week, Cytek Biosciences had 3 more articles in the media than Standard BioTools. MarketBeat recorded 6 mentions for Cytek Biosciences and 3 mentions for Standard BioTools. Standard BioTools' average media sentiment score of 0.72 beat Cytek Biosciences' score of 0.63 indicating that Cytek Biosciences is being referred to more favorably in the media.
Summary
Cytek Biosciences beats Standard BioTools on 10 of the 17 factors compared between the two stocks.
Get Standard BioTools News Delivered to You Automatically
Sign up to receive the latest news and ratings for LAB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Standard BioTools Competitors List
Related Companies and Tools
